Plandai Biotechnology, Inc.: 10-Q filed 2012-05-21
What Plandai Biotechnology, Inc. reported in its quarterly report filed 2012-05-21 (fiscal Q3 2012): 21 published measures, 53 facts as tagged in accession 0001262463-12-000205.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2012-05-21
- Fiscal period
- fiscal Q3 2012
- Accession
- 0001262463-12-000205 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Plandai Biotechnology, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 597,830 | USD | |
| At 2011-06-30 | 11,292 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 320,936 | USD | |
| At 2011-06-30 | 161,796 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 306,730 | USD | |
| At 2011-06-30 | -147,307 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | -2,434,421 | USD | 91 |
| 2011-07-01 to 2012-03-31 | -2,507,466 | USD | 275 |
| 2011-01-01 to 2011-03-31 | 57,175 | USD | 90 |
| 2010-07-01 to 2011-03-31 | 18,582 | USD | 274 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2012-03-31 | -138,458 | USD | 275 |
| 2010-07-01 to 2011-03-31 | 35,713 | USD | 274 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | 33,850 | USD | 91 |
| 2011-07-01 to 2012-03-31 | 49,017 | USD | 275 |
| 2011-01-01 to 2011-03-31 | 60,086 | USD | 90 |
| 2010-07-01 to 2011-03-31 | 59,574 | USD | 274 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2012-03-31 | 142,725 | USD | 275 |
| 2010-07-01 to 2011-03-31 | -35,581 | USD | 274 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2012-03-31 | 9,460 | USD | 275 |
| 2010-07-01 to 2011-03-31 | 0 | USD | 274 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | -6,835,853 | USD | |
| At 2011-06-30 | -4,354,758 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | 104,408,633 | shares | 91 |
| 2011-07-01 to 2012-03-31 | 87,064,120 | shares | 275 |
| 2011-01-01 to 2011-03-31 | 76,000,000 | shares | 90 |
| 2010-07-01 to 2011-03-31 | 76,000,000 | shares | 274 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 1,431 | USD | |
| At 2011-06-30 | 855 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2012-03-31 | 2,283,600 | USD | 275 |
| 2010-07-01 to 2011-03-31 | 0 | USD | 274 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | -2,434,421 | USD | 91 |
| 2011-07-01 to 2012-03-31 | -2,507,466 | USD | 275 |
| 2011-01-01 to 2011-03-31 | 57,175 | USD | 90 |
| 2010-07-01 to 2011-03-31 | 18,582 | USD | 274 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 596,399 | USD | |
| At 2011-06-30 | 10,437 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 320,936 | USD | |
| At 2011-06-30 | 161,796 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | 2,468,271 | USD | 91 |
| 2011-07-01 to 2012-03-31 | 2,556,483 | USD | 275 |
| 2011-01-01 to 2011-03-31 | 2,910 | USD | 90 |
| 2010-07-01 to 2011-03-31 | 40,993 | USD | 274 |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 7,131,810 | USD | |
| At 2011-06-30 | 4,199,851 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | -268 | USD |
Total equity including noncontrolling interests
Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | -276,994 | USD | |
| At 2011-06-30 | -150,504 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | 95,440 | USD | 91 |
| 2011-07-01 to 2012-03-31 | 107,263 | USD | 275 |
| 2011-01-01 to 2011-03-31 | 833 | USD | 90 |
| 2010-07-01 to 2011-03-31 | 3,002 | USD | 274 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2012-03-31 | 229 | USD | 275 |
| 2010-07-01 to 2011-03-31 | 0 | USD | 274 |
Inspect the source
- Entity
- Plandai Biotechnology, Inc. / CIK 0001317880
- Captured
- SEC response SHA-256
e24b67d85b1d2e03527e4a75cf3f495a155375a1a0e10302aff7f4632fcf21aa
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001317880.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))